Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines
Invivyd; Pemgarda; VYD2311; monoclonal antibody; COVID-19; vaccine alternatives; immune compromise; long-acting protection; phase 1/2 clinical data
TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects
TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug
Bayer’s BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move
BlueRock Therapeutics; Bayer; layoffs; biotech; Cambridge research labs; cell therapy; streamlining; bemdaneprocel; OpCT-001; pharmaceutical industry
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal
Longevity Biotech; Nasdaq; SPAC deal; public listing; FutureTech II Acquisition Corp.; clinical development; biotech merger; age-related diseases
Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader
Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations
Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies
Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy
FDA Investigates Patient Deaths Linked to Sarepta’s Elevidys Gene Therapy for Duchenne Muscular Dystrophy
FDA; Sarepta; Elevidys; Duchenne muscular dystrophy; gene therapy; patient deaths; acute liver failure; liver toxicity; regulatory investigation; non-ambulatory patients
Kymera Faces Sanofi Setback but Secures $750M Gilead Oncology Deal
Kymera; Sanofi; Gilead; molecular glue degrader; CDK2; oncology; deal; protein degrader
Leap Therapeutics Slashes 75% of Workforce, Ends Clinical Trial, Considers Strategic Options
Leap Therapeutics; workforce reduction; biotech layoffs; clinical trial; strategic alternatives; sirexatamab; FL-501; R&D wind down
Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical
Nektar Therapeutics; Rezpegaldesleukin; Rezpeg; Phase IIb trial; eczema; atopic dermatitis; clinical trial; EASI score; Dupixent; analyst skepticism; Lilly partnership